Chemical Exchange Saturation Transfer (CEST) MRI for the Characterization Small Renal Masses

项目摘要 德克萨斯大学西南分校科学家和临床医生之间的学术和产业合作 (UTSW)医学中心和飞利浦研究汉堡和飞利浦北美(飞利浦)已经成立 为了翻译新的分子磁共振成像方法，化学交换饱和 转移(CEST)，成为评估肾脏小肿块(SRM)的临床工具。CEST已经 证明了在神经肿瘤学应用的可行性。SRM的管理具有挑战性，因为 其中大部分是良性或惰性恶性肿瘤，导致患者暴露于 活组织检查和手术导致的不必要的发病率。良性肿瘤与惰性肿瘤的非侵袭性鉴别 侵袭性肿瘤将允许更好的风险分层和患者管理。虽然是小说，但CEST 已经被某些临床中心用于神经肿瘤学的评估。最近，我们的团队 展示了CEST在乳房病变定性方面的前景。在此，我们建议扩大 CEST在肾脏肿瘤学中的应用通过解决CEST在肾脏肿瘤中应用的内在挑战 并通过优化SRM患者的CEST来实现这一目标。 我们的假设是CEST-MRI技术的发展可以观察到侵袭性肿瘤 固体火箭发动机内的微环境。我们的目标是推动CEST方法成为全面SRM的一部分 评估方案。该项目的目标将通过以下具体目标实现： 目的1：在3T人体磁共振成像系统上建立和优化用于SRM的CEST方法学。 这是技术发展目标，我们将在此评估几种解决主要问题的方法 与CEST向肾脏肿瘤学应用的转换相关：(I)提高分辨率和脂肪分离， (Ii)使用伪笛卡尔和欠采样算法加速捕获，(Iii)运动校正和 (4)先进的Z谱分析方法。 目的：评价优化的CEST-MRI作为预测SRM病理改变的生物标志物的价值。 目的是将CEST技术转化为SRM患者：(I)对优化的 在一组SRM患者中：(Ii)CEST-MRI测量与组织病理学结果的相关性 CEST-MRI与糖原沉积的相关性研究

Project Summary An Academic-Industrial partnership between scientists and clinicians at the University of Texas Southwestern (UTSW) Medical Center and Philips Research Hamburg and Philips North America (Philips) has been formed with the purpose of translating the novel molecular MR imaging method, Chemical Exchange Saturation Transfer (CEST), into a clinical tool for the assessment of Small Renal Masses (SRMs). CEST has already demonstrated feasibility in neurooncology applications. The management of SRMs is challenging because a substantial number of them are benign or indolent malignant tumors, leading to patient exposure to unnecessary morbidity from biopsies and surgery. Non-invasive distinction between benign/indolent tumors and aggressive tumors would allow for better risk stratification and patient management. While novel, CEST has already been adopted by certain clinical centers for assessment in neuro oncology. Recently, our group demonstrated the promise of CEST to the characterization of breast lesions. Here, we propose to broaden the application of CEST to renal oncology by addressing the inherent challenges of application of CEST in the abdomen and by optimizing CEST in patients with SRMs. Our hypothesis is that technical development of CEST-MRI allows observation of aggressive tumor microenvironment in SRM. Our goal is to advance CEST methodology to become a part of comprehensive SRM evaluation protocol. The goals of the project will be achieved via the following Specific Aims: Aim 1: To develop and optimize CEST methodology for SRMs on 3T human MRI system. This is technical development Aim, where we will evaluate several approaches addressing major issues associated with translation of CEST to kidney oncology applications: (i) improved resolution and fat separation, (ii) acceleration of acquisition using pseudo-cartesian and undersampled algorithms,(iii) motion correction and (iv) advanced Z-spectrum analysis methods. Aim 2: To evaluate the optimized CEST-MRI as a predictive biomarker of SRM hystology. The Aim's focus in on the translation of the CEST technology to SRM patients: (i) evaluation of the optimized in a group of SRM patients: (ii) correlation of the CEST-MRI measurements with histopathology results and correlation of CEST-MRI with glycogen deposition.